ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2617

Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial

Erica Bush 1, Vivek Nagaraja 1, Robert Lafyatis 2 and Dinesh Khanna3, 1University of Michigan, Ann Arbor, MI, 2University of Pittsburgh Department of Medicine, Pittsburgh, 3Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Scleredema and clinical trials

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Modified Rodnan skin score (mRSS) is used as primary and secondary outcome measure in different trials of diffuse cutaneous systemic sclerosis (dcSSc) 1. As part of a Phase I/II trial assessing the safety of tofacitinib 5 mg twice a day versus placebo in dcSSc (clinicaltrials.gov NCT032740762), we assessed the performance of 3 different methods of scoring the modified Rodnan skin score (mRSS)1.

Methods: A 6-month, double-blind, randomized placebo-controlled trial was conducted in dcSSc with disease duration of ≤ 60 months (defined as first non−Raynaud phenomenon) and mRSS ≥ 10 and ≤ 45 units.  Efficacy end point included the change in the mRSS at 6 months. Each anatomical area was scored as Global Average score where the examiner takes average of the area; Maximum score where an examiner scores the area according to the most severe local involvement; and the Representative area where the examiner assigns a score that is most representative  of the area. Responsiveness to change was evaluated using the effect size (ES) and standardized response mean (SRM). Both indices are ratios of observed change to a measure of variance (also known as signal to noise).  For two indices, the numerator is the mean change from the baseline to Month 6 for mRSS and the denominators are the standard deviation at baseline (ES) and  the standard deviation of change (SRM). Cohen’s rule-of-thumb for interpreting responsiveness to change was applied to determine the magnitude of change where 0.20-0.49 represents a small change, 0.50-0.79 a medium change, and 0.80 or greater a large change.

Results: 15 participants were randomized (2:1; 10 to TOFA and 5 to PLA) and formed the mITT group; 10 (100%) and 4 (80%) completed the 6-month treatment period in TOFA and PLA groups, respectively. The mean baseline scores were similar in the Global Average and Representative groups and higher in the Maximum group (Table 1). Using the ES, the magnitude of responsiveness was similar in all 3 groups (Medium change). Using the SRM, the magnitude of change was numerically greater in the Representative and Maximum groups (Large change) vs. Global Average (Medium change).

Conclusion: In a small trial of 15 participants, all 3 methods to score the mRSS yielded similar magnitude of responsiveness to change. The mRSS was conducted by experienced researchers in this trial and these results should be validated in a larger trial with multiple centers.

  1. Khanna D, et al. JSRD 2017
  2. Khanna D, et al Submitted American College of Rheumatology 2019

Acknowledgment: Dr. Khanna is funded by NIAMS K24 AR063120 and R01 AR 070470.


Respon_MRSS_tofa_Final TABLE

Table 1: Responsiveness to change in the mRSS using different scoring methods


Disclosure: E. Bush, None; V. Nagaraja, None; R. Lafyatis, BioDiscovery- Forbius, 5, Formation Biologics, 5, FBM Therapeutics, 5; D. Khanna, Acceleron, 5, 8, Acceleron Pharma, 5, Actelion, 5, 8, Actelion Pharmaceuticals, 5, Astra Zeneca, 5, Bayer, 2, 5, 8, Behring, 5, Blade, 5, Blade Therapeutics, 5, 8, Blade therapeutics, 5, BMS, 2, 5, 8, Boehringer Ingelham, 5, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 5, Celgene, 5, 8, ChemomAB, 5, ChemomAb, 5, CiviBioPharma, Inc., 3, Corbus, 5, Corobus, 5, Corpus, 5, CSL Behring, 5, 8, Curizon, 5, Curzion, 5, Cytori, 5, 8, Eicos, 4, Eicos Sciences, 4, Eicos Sciences, Inc, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc, 1, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc., 1, Eicos, Inc, 4, Eicos, Inc., 5, 8, Eicos, INC., 4, Galapagos, 5, Genentech, 5, Genentech/Roche, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 2, 5, Mitsubishi Tanabe Pharma, 5, Mitsubishi Tanabe Pharma Dev America, 5, Mitsubishi Tanabe Pharma Development America, 5, Mitsubishi Tanabi, 5, NIH K24 and R01, 2, NIH / NIAMS K24 AR-063120, 2, NIH/NIAMS R01& K24, 2, Pfizer, 2, 5, Sanofi, 5, Sanofi Aventis, 5, Sanofi-Aventis, 5, 8, Sanofi-Aventis/Genzyme, 5, UCB, 5, UCB Pharma, 5.

To cite this abstract in AMA style:

Bush E, Nagaraja V, Lafyatis R, Khanna D. Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/responsiveness-to-change-of-the-modified-rodnan-skin-score-in-a-phase-i-ii-double-blind-randomized-placebo-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/responsiveness-to-change-of-the-modified-rodnan-skin-score-in-a-phase-i-ii-double-blind-randomized-placebo-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology